about
Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic InteractionsTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayReconstruction of Tissue-Specific Metabolic Networks Using CORDAA tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancerQuantitative real-time RT-PCR of CD24 mRNA in the detection of prostate cancerIntegrative molecular concept modeling of prostate cancer progression.Detecting disease associated modules and prioritizing active genes based on high throughput data.New developments in the medical management of prostate cancer.Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasiaNemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cellsPrognostic factors in prostate cancer.Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas.Aberrant DNA methylation and prostate cancer.DNA methylation changes in prostate cancer: current developments and future clinical implementation.FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.Genome-wide approaches for identification of nuclear receptor target genes.Analysis of cell cycle phases and progression in cultured mammalian cells.New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication'Insignificant' prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy.MicroRNA-449a enhances radiosensitivity by downregulation of c-Myc in prostate cancer cellsA global view of transcriptional regulation by nuclear receptors: gene expression, factor localization, and DNA sequence analysis.Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling.An improved method for constructing tissue microarrays from prostate needle biopsy specimens.Markers for detection of prostate cancer.Correlation of MR imaging and MR spectroscopic imaging findings with Ki-67, phospho-Akt, and androgen receptor expression in prostate cancer.Ultrasound-Mediated Mesenchymal Stem Cells Transfection as a Targeted Cancer Therapy Platform.Effect of the number of biopsy cores on prostate cancer detection and staging.Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Cancer Development and Tumor Angiogenesis.Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum.MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas.Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer.Analysis of the specific pathways and networks of prostate cancer for gene expression profiles in the Chinese population.The emerging role of Nemo-like kinase (NLK) in the regulation of cancers.Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.Dystroglycan function is a novel determinant of tumor growth and behavior in prostate cancer.Gene network and canonical pathway analysis in prostate cancer: a microarray study.Effect of paclitaxel on intracellular localization of c-Myc and P-c-Myc in prostate carcinoma cell lines.Human cytomegalovirus infection alters PC3 prostate carcinoma cell adhesion to endothelial cells and extracellular matrix.
P2860
Q26766242-CCBA5C93-81CE-4C57-81A9-EF80474273A2Q28382812-054CA767-325D-48F9-9C6C-61CE5B90C5E5Q28388815-4155D4D0-B3D3-4977-88C4-1071AEDF6EF3Q28478225-DCE0F0FA-AB12-48D7-BF6B-52B99CD128E0Q33236640-3995D366-6066-43E7-A4B8-A1D08A4CCBBEQ33266777-C6334CCE-DC76-49FE-BF24-F1703DD1133FQ33523628-D752CA89-F845-4ACB-9591-999BE1521F51Q33566738-3616730B-4EA6-46D1-AD4A-67A6157CDADEQ33685303-D08E79E5-BCBE-4701-9186-6937C823BA3AQ33730212-674EB20C-78F8-4944-87A6-DF1397851D1BQ34012237-ABEE6613-CFDD-48D7-B2FF-05378CECC842Q34682069-54BB391B-D5AA-4E54-AE9E-46AC9AB7D396Q35039874-8B9D5B03-CC33-4136-BD98-74C52E89185CQ35560819-F4F84AD6-7A7C-4542-97B3-0A42BD34A367Q35636543-FAD26CE3-0F14-43B4-A965-4BA149EF17D5Q36486689-B76F47BE-0D45-437F-BFE7-D3BE385A12E4Q36544557-62B87281-0D69-4C76-B88D-E9F366573F9AQ36692793-D9BBF670-6DDF-4345-9291-F3EA73A1E948Q36734036-3E2ED1FE-A7A7-45CD-90AD-FAD12C1876E9Q36771260-179CE603-5413-4B63-A4A5-AE7F66094BFCQ36959452-FD638450-2BC1-4E66-BB04-C035F209DD3EQ37095266-4E4A8EB2-C839-4A55-9B05-EA2326D40EBCQ37246666-C284060A-F6C9-4A21-828E-122FA56D27A3Q37260048-94CB9B9A-793C-486E-807B-72C2FA780629Q37328403-B2D0278D-274D-48FC-936F-7438944C2BD9Q37401554-9BAA0202-CB8C-486D-BAEB-668B7C315451Q37627675-E1099DF1-CAA3-4B9B-9B43-42B286F1E1BBQ37707378-F0769BA7-29FB-4D79-9CE2-5CBE0068A0F2Q37721103-FB877C61-54B3-4D4B-AC84-80EF3B5FB27FQ37882512-0CF7947F-2FFC-49E0-975A-9DD9FE146774Q38147318-45B3F690-C3C7-4F50-A502-BC23C4F2F25EQ38359505-307698FE-947E-4F75-B8A2-230A7FEDCD2EQ38500161-6E6B1BFC-9631-450E-BE25-079891A1F1B7Q38596991-BA3EA8FD-F867-4428-AAA4-FBA270A4D6FFQ38807901-DE109237-6699-4837-AE70-8A8844480EA0Q39200185-2EC67CEC-CD6D-42AD-90FA-18850ED25F22Q39274601-1C4E183F-F112-4CA9-A7F5-7906DA79D2DAQ40097302-D519FD43-FE92-4C76-B883-76E4138FDF9AQ40150681-05C4FED0-D358-4A72-942A-B9C71F4AF21AQ40221683-859E5ED9-C485-4552-9C8E-A79F4EE6234F
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Molecular markers of prostate cancer outcome.
@ast
Molecular markers of prostate cancer outcome.
@en
type
label
Molecular markers of prostate cancer outcome.
@ast
Molecular markers of prostate cancer outcome.
@en
prefLabel
Molecular markers of prostate cancer outcome.
@ast
Molecular markers of prostate cancer outcome.
@en
P2093
P1476
Molecular markers of prostate cancer outcome.
@en
P2093
David I Quinn
Robert L Sutherland
Susan M Henshall
P304
P356
10.1016/J.EJCA.2004.12.035
P577
2005-04-01T00:00:00Z